Interview With Dan Troy: Former FDA Chief Counsel On Enforcement, Generic Drugs, First Amendment
Executive Summary
Former FDA Chief Counsel Dan Troy met with the editors of "The Pink Sheet" Jan. 3 to discuss his experience at FDA and his expectations for the future of the agency. Troy subsequently joined the firm of Sidley Austin Brown & Wood.
You may also be interested in...
FDA Re-Examining Citizen Petition Process To Speed Generic Approvals
FDA is taking another look at its citizen petition review process in an attempt to expedite decisions on generic drug applications, Center for Drug Evaluation & Research Acting Director Steven Galson told the Generic Pharmaceutical Association's annual meeting Feb. 25 in Boca Raton, Fla
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.